Artwork

Innhold levert av Audioboom and Pharmaceutical Executive Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Audioboom and Pharmaceutical Executive Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

The Weight-Loss Gold Rush: Legal and Regulatory Implications

17:10
 
Del
 

Manage episode 428347348 series 2084987
Innhold levert av Audioboom and Pharmaceutical Executive Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Audioboom and Pharmaceutical Executive Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
  • Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
  • How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
  • What needs to be done for GLP-1s to be covered
  • Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
  • Advice for investors and financiers who are considering entering the weight-loss medication market
  continue reading

173 episoder

Artwork
iconDel
 
Manage episode 428347348 series 2084987
Innhold levert av Audioboom and Pharmaceutical Executive Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Audioboom and Pharmaceutical Executive Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
  • Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
  • How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
  • What needs to be done for GLP-1s to be covered
  • Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
  • Advice for investors and financiers who are considering entering the weight-loss medication market
  continue reading

173 episoder

Kaikki jaksot

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett